Exelixis (EXEL) Research & Development (2010 - 2026)
Exelixis' Research & Development was $211.99 million in Q2 2027, up 5.8% from $200.36 million a year earlier and up 6.0% from the prior quarter.
Powered by 
Analysis
Exelixis (EXEL) Research & Development (2010 - 2026) Analysis & Trends
On a trailing twelve-month basis, Exelixis' Research & Development was $824.32 million through Jul 3, 2026, down 6.8% year-over-year; for FY2026, it came in at $825 million, down 9.4% from FY2025.
- Research & Development shows a five-year compound annual growth rate of 3.5% (FY2021 to FY2026).
- In earlier years, Research & Development was $910.41 million in FY2025, $1.04 billion in FY2023 (+17.1%) and $891.81 million in FY2022 (+28.6%).
- Quarterly Research & Development has moved between $199.16 million (Q3 2026) and $249 million (Q4 2025) over five years.
- Compared with a year earlier, Research & Development was higher in 1 of the last six quarters, with an average decline of 6.1%.
- Per Business Quant data, EXEL's Research & Development in the three quarters before Q2 2027 was $199.92 million (Q1 2027), $213.25 million (Q4 2026) and $199.16 million (Q3 2026).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Exelixis | 14.53 Bn | 10.86 Bn | 608.03 Mn | 211.99 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jul 3, 2026 | 211.99 Mn |
| Apr 3, 2026 | 199.92 Mn |
| Jan 2, 2026 | 213.25 Mn |
| Oct 3, 2025 | 199.16 Mn |
| Jul 4, 2025 | 200.36 Mn |
| Apr 4, 2025 | 212.23 Mn |
| Jan 3, 2025 | 249.00 Mn |
| Sep 27, 2024 | 222.57 Mn |
| Jun 28, 2024 | 211.15 Mn |
| Mar 29, 2024 | 227.69 Mn |
| Dec 29, 2023 | 244.67 Mn |
| Sep 29, 2023 | 332.59 Mn |
| Jun 30, 2023 | 232.57 Mn |
| Mar 31, 2023 | 234.25 Mn |
| Dec 30, 2022 | 336.82 Mn |
| Sep 30, 2022 | 198.84 Mn |
| Jul 1, 2022 | 199.48 Mn |
| Apr 1, 2022 | 156.67 Mn |
| Dec 31, 2021 | 222.27 Mn |
| Oct 1, 2021 | 163.37 Mn |
API Access
Exelixis Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=EXEL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "EXEL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=EXEL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();